Glipy Tablet contains Vildagliptin 50 mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by enhancing the incretin system, thereby increasing insulin secretion and decreasing glucagon levels in a glucose-dependent manner. This mechanism helps improve glycemic control without causing significant hypoglycemia. Glipy Tablet is indicated as monotherapy or as an adjunct to other antidiabetic agents such as metformin or sulfonylureas when diet and exercise alone do not provide adequate glycemic control. It is particularly beneficial for patients who require improved postprandial glucose regulation. The recommended dose is typically 50 mg twice daily, but dosing may be adjusted based on renal function and clinical response. Common adverse effects include headache, dizziness, and gastrointestinal disturbances; however, it is generally well tolerated. Caution is advised in patients with renal impairment, and regular monitoring of renal function is recommended. Glipy Tablet should be used under medical supervision, with lifestyle modifications including diet and exercise maintained to optimize therapeutic outcomes in type 2 diabetes management.